Leadership

Management Team

Leonard Bell, M.D., Chief Executive Officer

 

Leonard Bell, M.D. is the Chief Executive Officer and principal founder of Alexion Pharmaceuticals. Under his continuous leadership since 1992, Alexion has become a fast-growing and profitable global biopharmaceutical company, with more than 1,600 employees serving patients in 50 countries through fully integrated research, discovery, development, manufacturing and commercial capabilities.

Dr. Bell’s combination of scientific, clinical, regulatory and business skills have been central to Alexion’s accomplishments, from the early discovery and development of Soliris® (eculizumab) to the subsequent building and management of what is now a global commercial organization. Dr. Bell has emphasized strong growth and highly controlled use of financial resources as the Company continues the ongoing global launches of Soliris in PNH and aHUS while broadening and accelerating Alexion’s development of new indications for Soliris and additional innovative therapeutic candidates with transformative potential for patients with severe and ultra-rare disorders.

Prior to founding Alexion, Dr. Bell was an attending physician at Yale-New Haven Hospital and Assistant Professor of Medicine and Pathology at the Yale University School of Medicine, where he also received his M.D. degree. He remains on the faculty of the Yale University School of Medicine as an Adjunct Assistant Professor of Medicine and Pathology. Dr. Bell received his A.B. degree from Brown University.

 

David Hallal, Chief Operating Officer

 

David Hallal is Chief Operating Officer of Alexion Pharmaceuticals. In this position, he leads key enterprise-wide initiatives that focus on diverse aspects of our operations. Mr. Hallal also leads our commercial organization globally, and also has responsibility for all country operations in each of Alexion’s affiliates in Europe/Middle East/Africa (EMEA), Japan, Australasia and Latin America. Mr. Hallal joined Alexion in 2006. Under his leadership, he formulated and implemented from inception Alexion’s global commercial organization to support Soliris® (eculizumab) as our industry’s most successful ultra-orphan drug launch, currently approved to treat patients with PNH and aHUS.

Mr. Hallal has more than 25 years of experience in the biopharmaceutical industry. Before joining Alexon in 2006, Mr. Hallal served as Vice President, Sales at OSI Eyetech, and held various commercial leadership positions at Amgen and Biogen Idec where he was involved in multiple blockbuster product launches in the areas of hematology, oncology, nephrology and immunology.

Mr. Hallal holds a BA from the University of New Hampshire.

 

Vikas Sinha, Executive Vice President, Chief Financial Officer

 

Vikas Sinha is Executive Vice President, Chief Financial Officer of Alexion Pharmaceuticals, with responsibility for global financial management, corporate & strategic development, treasury, internal audit, investor relations, information technology, engineering, and real estate & security activities. Mr. Sinha has built these functions since 2005, when Alexion was based only in the US and had no approved product for sale.

Today, he leads global teams working in more than 20 countries to support the launches of Soliris in PNH and aHUS while building out Alexion’s global capabilities to support additional indications for Soliris and the launch of new transformative therapeutic candidates resulting from both internal development and strategic acquisitions.

Prior to joining Alexion, Mr. Sinha spent 11 years with Bayer AG in the US, Japan, Germany and Canada, rising to the position of Vice President and CFO of the Bayer Pharmaceutical organization in Japan and later, the US. Prior to Bayer, Mr. Sinha also held several positions of increasing responsibility with ANZ Bank and Citibank in South Asia.

Mr. Sinha holds a master's degree in business administration from the Asian Institute of Management. He is also a qualified Chartered Accountant from the Institute of Chartered Accountants of India and a Certified Public Accountant in the US.

 

Stephen Squinto, Ph.D., Executive Vice President, Chief Global Operations Officer

 

Stephen Squinto, Ph.D. is co-founder of Alexion Pharmaceuticals and currently serves as Executive Vice President and Chief Global Operations Officer. Dr. Squinto is responsible for Alexion’s Global Quality, Manufacturing and Project Management functions.

Since co-founding Alexion with CEO Leonard Bell in 1992, Dr. Squinto has held several leadership positions guiding the company's research and development programs across the Alexion pipeline, including Executive Vice President, Head of R&D, during which he led the Company’s program that resulted in Soliris® approvals for patients with atypical hemolytic uremic syndrome in the US, European Union and Japan.

Prior to co-founding Alexion, Dr. Squinto held various scientific positions at Regeneron Pharmaceuticals, Inc., focused on drug discovery. He has also served as Assistant Professor of Biochemistry and Molecular Biology at Louisiana State University Medical Center. Dr. Squinto is a prominent researcher in molecular and cellular biology, with more than 70 scientific papers resulting from his work. He also serves on the Board of Directors of the regional Chapter of the Juvenile Diabetes Research Foundation.

Dr. Squinto received a bachelor's degree in chemistry and a doctorate degree in biochemistry and biophysics from Loyola University in Chicago.

 

Martin Mackay, Ph.D., Executive Vice President, Global Head of Research & Development

 

Martin Mackay, Ph.D. joined Alexion in May 2013 as Executive Vice President, Global Head of Research & Development.  In his role, Dr. Mackay is focused on significantly expanding Alexion’s global research and development organization, with a goal of accelerating the simultaneous development of multiple life-transforming drug candidates in debilitating and life-threatening ultra-rare disorders across a range of therapeutic areas. Dr. Mackay has more than 30 years of experience in drug discovery and development on a global scale.

Prior to joining Alexion, Dr. Mackay served as President, Research and Development at AstraZeneca, where he led all R&D functions worldwide, including discovery research, clinical development, regulatory affairs and key related R&D functions. He also held positions of increasing responsibility at Pfizer, rising to the position of President, Head of Pfizer Pharmatherapeutics, R&D, where he oversaw all aspects of small molecule discovery and development across multiple therapeutic areas. Earlier in his career, Dr. Mackay worked in the CIBA organization (now Novartis) and held positions within academia.

Dr. Mackay earned a Microbiology First Class Honors Degree from Heriot-Watt University, Scotland, and a Ph.D. in Molecular Genetics from the University of Edinburgh, Scotland.

 

Clare Carmichael, Executive Vice President, Chief Human Resources Officer

 

Clare Carmichael is Executive Vice President, Chief Human Resources Officer of Alexion Pharmaceuticals. She is responsible for Human Resources on a global basis, with the goal of continuing to build a cohesive organization with integrated, high performance teams.

Ms. Carmichael brings 30 years of HR experience with global pharmaceutical and biotech organizations to the organization. Prior to joining Alexion, she was SVP, Global Human Resources at Watson Pharmaceuticals, where she established and executed a strategy to successfully transition the workforce from a siloed U.S.-centric operation to a globally-focused matrix organization. Clare also held several HR positions at Schering-Plough, including Vice President of Global Human Resources at the Schering-Plough Research Institute, where she was selected for the global HR lead role for R&D to help drive cultural change in the organization. While at Schering-Plough, she also spearheaded integration activities when the company acquired Organon Biosciences. Clare also worked as the Vice President of HR at Eyetech Pharmaceuticals, leading the human resources function in the company from its post-IPO phase into the commercial phases of development and in Human Resources at Pharmacia Corporation.

Ms. Carmichael received a bachelor’s degree from Rider University and completed the University of Michigan Human Resources Executive Program.

 

John Moriarty, Executive Vice President, General Counsel

 

John Moriarty is Executive Vice President, General Counsel of Alexion. In his role, he is responsible for overseeing all global legal matters as well as the Global Government Affairs and Corporate Communications teams. Since joining Alexion in 2012, his focus has been on developing these functions to support an increasing number of initiatives on behalf of patients in a growing number of countries.

Prior to joining Alexion, Mr. Moriarty was General Counsel and Chief Legal Officer at Elan Corporation plc, and served as a member of Elan’s Executive Management team. In his time at Elan, he was also Senior Vice President of Law, Litigation and Commercial Operations. Prior to that, Mr. Moriarty held several legal leadership positions at Amgen focused on litigation, and led the Amgen legal teams for the company’s commercial oncology, nephrology and hematology businesses. He has also worked as an attorney in the healthcare practice of a national law firm’s Washington, DC and New York offices and was a healthcare fraud prosecutor in the US Attorney’s Office and the Virginia Attorney General’s Office.

Mr. Moriarty holds a J.D. from the University of Georgia School of Law and a B.A. from the University of Virginia.

 

Saqib Islam, Senior Vice President, Chief Strategy and Portfolio Officer

 

Saqib Islam is Senior Vice President, Chief Strategy and Portfolio Officer of Alexion Pharmaceuticals. His role at the company is to execute Alexion’s corporate growth strategies and contribute to its assessment and management of global operations.

Prior to joining Alexion, Mr. Islam worked for 18 years in international business management with a focus on business development, strategic decision-making and planning, and capital markets. He has an extensive background in the healthcare banking sector, having held positions of increasing responsibility in the investment banking divisions of Merrill Lynch, Morgan Stanley, and most recently, Credit Suisse Securities. Earlier in his career, Mr. Islam provided strategic analysis and advice to client firms across diverse industry segments for The Boston Consulting Group.

Mr. Islam received a bachelor’s degree from McGill University and a J.D. from Columbia Law School.

 

Edward Miller, Senior Vice President, Global Chief Compliance Officer

 

Edward Miller is Senior Vice President, Global Chief Compliance Officer. In his role, he leads all compliance functions globally for Alexion. Upon joining the company in 2014, Mr. Miller continued to build upon Alexion’s strong compliance program established over the past several years and reinforce the company’s commitment to ethical business practices.

Prior to joining Alexion, Mr. Miller served for 14 years at Boehringer Ingelheim, holding numerous compliance and legal leadership positions, including Vice President, Associate General Counsel, Global Litigation & Government Investigations; Vice President/Acting Global Compliance Officer; Vice President, Chief Compliance Officer and Head of Litigation; and Chief Compliance Officer, Head of Litigation. During his tenure there, he served as Boehringer’s first U.S. Chief Compliance Officer and also helped build a best-in-class global compliance function while assigned to Boehringer’s worldwide headquarters in Germany. Previously, Mr. Miller was a Senior Trial Attorney at the U.S. Department of Justice in Washington, D.C.

He obtained his undergraduate degree from Princeton University and law degree from Rutgers University School of Law.

 


Board of Directors

Max Link, Ph.D., Chairman of the Board of Directors

 

Max Link, Ph.D. has been the Chairman of Alexion’s board of directors since December 2002 and a director of Alexion since April 1992. He is currently the Scientific Advisor of Excalibur Fund Managers Limited and of Excalibur Group Holdings Ltd. Prior to joining Alexion, Dr. Link was Chairman of the Board and CEO of Centerpulse AG, a medical implant company, as well as the CEO of Corange (Bermuda), the parent company of Boehringer Mannheim Therapeutics, Boehringer Mannheim Diagnostics and DePuy Orthopedics. Previous to that, he was Chairman of the Board of Sandoz Pharma, Ltd., CEO of Sandoz Pharma and a member of the Executive Board of Sandoz, Ltd., Basel. Dr. Link has also worked in various capacities within Sandoz in the United States, including as the President and CEO. He has been actively involved as a Director in numerous development-stage companies within the biopharmaceutical and medical device fields, both at the domestical and international level , since 1994. Dr. Link currently serves as Chairman of the Board of Directors for Amedica, Celsion Corporation and Cytrx Corporation,and is on the board at Mipharm S. p.A.

He holds a Ph.D. in economics from University of St. Gallen (Switzerland).

 

Leonard Bell, M.D., Chief Executive Officer

 

Leonard Bell, M.D. is the principal founder of Alexion Pharmaceuticals and has been its Chief Executive Officer since 1992. Under his leadership, Alexion has emerged as a fast-growing and profitable global biopharmaceutical company through fully integrated research, discovery, development, manufacturing and commercial capabilities.

Dr. Bell’s scientific, clinical, regulatory and business skills have been central to Alexion’s accomplishments, from the early discovery and development of Soliris® (eculizumab) to the subsequent building and managing of what is now a global commercial organization. Dr. Bell has emphasized strong growth and highly controlled use of financial resources as the Company continues the ongoing global launches of Soliris in PNH and aHUS. He has done so while broadening and accelerating Alexion’s development of new indications for Soliris and additional innovative therapeutic candidates with transformative potential for patients with severe and ultra-rare disorders.

Prior to the founding of Alexion, Dr. Bell was an attending physician at Yale-New Haven Hospital and Assistant Professor of Medicine and Pathology at the Yale University School of Medicine, where he also received his M.D. degree. He remains on the faculty of the Yale University School of Medicine as an Adjunct Assistant Professor of Medicine and Pathology. Dr. Bell received his A.B. degree from Brown University.

 

David R. Brennan, Director

 

David R. Brennan has been a director of Alexion since July 2014. He most recently served as Chief Executive Officer and Executive Director of AstraZeneca PLC, one of the world’s largest pharmaceutical companies, from 2006 to 2012. Mr. Brennan worked for AstraZeneca in increasing roles of responsibility from 1992 through 2012, including as Executive Vice President of North America from 2001 to 2006, and as Senior Vice President of Commercialization and Portfolio Management from 1999 to 2001. Prior to the merger of Astra AB and Zeneca Plc, he served as Senior Vice President of Business Planning and Development of Astra Pharmaceuticals LP, the American subsidiary of Astra AB. Mr. Brennan began his career in 1975 at Merck and Co. Inc., where he rose from Sales Representative in the U.S. Division to General Manager of Chibret International, a French subsidiary of Merck. Mr. Brennan currently serves on the Board of Directors of Innocoll, Inc. and Insmed Incorporated, and previously served on the Board of Directors of AstraZeneca PLC, Reed Elsevier PLC, and the Pharmaceutical Research & Manufacturers of America (PhRMA).

He received a BA in business administration from Gettysburg College, where he is a member of the Board of Trustees.

 

M. Michele Burns, Director

 

M. Michele Burns has been a director of Alexion since July 2014. She currently serves as Center Fellow and Strategic Advisor, Stanford University Center on Longevity. She served in senior executive roles with Marsh & McLennan Companies, Inc. ("MMC"), including as Chief Executive Officer, Retirement Policy Center sponsored by MMC from 2011 to 2014, Chairwoman and Chief Executive Officer of Mercer LLC, a subsidiary of MMC, from 2006 to 2011, and Executive Vice President and Chief Financial Officer of MMC in 2006. From 2004 to 2006, Ms. Burns served as Executive Vice President, Chief Financial and Chief Restructuring Officer for Mirant Corporation. From 1999 to 2004 she worked in increasing roles of responsibility at Delta Air Lines, serving as Executive Vice President and Chief Financial Officer of Delta from 2000 to 2004. Ms. Burns began her career with Arthur Andersen, and over an 18-year tenure rose to Senior Partner, leading Andersen's Southern Region Federal Tax Practice, heading its U.S. Healthcare Tax Practice and its Southeastern Region Financial Services Tax Practice, and serving on its Global Advisory Council. Ms. Burns currently serves on the Board of Directors of The Goldman Sachs Group, Inc., Cisco Systems, Inc., and Circle Internet Financial, Ltd. She also serves on the Executive Board and as Treasurer of the Elton John Aids Foundation. She previously served on the Board of Directors of Wal-Mart Stores, Inc., Ivan Allen Company, and Orbitz, LLC.

Ms. Burns received a BA in business administration and a Master of Accountancy from the University of Georgia.

 

Christopher J. Coughlin, Director

 

Christopher J. Coughlin has been a director of Alexion since July 2014. He is currently a Senior Advisor, McKinsey & Co., where he has served since 2012. He served as Advisor to the Chairman and CEO of Tyco International Ltd., a global provider of diversified products, services and industries, from 2010 to 2012, and as Executive Vice President and Chief Financial Officer of Tyco from 2005 to 2010 and during a period of significant international growth and restructuring. Mr. Coughlin previously served at the Interpublic Group of Companies, Inc. as Executive Vice President, Chief Operating Officer from 2003 to 2004. From 1998 to 2003, he served as Executive Vice President and Chief Financial Officer of Pharmacia Corporation. From 1997 to1998 he was President, International at Nabisco Group Holdings and from 1996 to 1997 was Executive Vice President and Chief Financial Officer of Nabisco. From 1981 to 1996, Mr. Coughlin held various positions with Sterling Winthrop Incorporated, including Chief Financial Officer. Mr. Coughlin currently serves on the Board of Directors of Actavis plc, Covidien, and Dun & Bradstreet. He previously served on the Board of Directors of Forest Laboratories (acquired by Actavis plc), Dipexium Pharmaceuticals, Inc., The Interpublic Group of Companies, Monsanto Company, and Perrigo Company.

Mr. Coughlin received a BS in accounting from Boston College.

 

David Hallal, Chief Operating Officer

 

David Hallal has been Chief Operating Officer of Alexion Pharmaceuticals since September 2014. In this position, he leads key enterprise-wide initiatives that focus on diverse aspects of our operations. Mr. Hallal also leads our commercial organization globally, and also has responsibility for all country operations in each of Alexion’s affiliates in Europe/Middle East/Africa (EMEA), Japan, Australasia and Latin America. Mr. Hallal joined Alexion in 2006. Under his leadership, he formulated and implemented from inception Alexion’s global commercial organization to support Soliris® (eculizumab) as our industry’s most successful ultra-orphan drug launch, currently approved to treat patients with PNH and aHUS.

Mr. Hallal has more than 25 years of experience in the biopharmaceutical industry. Before joining Alexon in 2006, Mr. Hallal served as Vice President, Sales at OSI Eyetech, and held various commercial leadership positions at Amgen and Biogen Idec where he was involved in multiple blockbuster product launches in the areas of hematology, oncology, nephrology and immunology.

Mr. Hallal holds a BA from the University of New Hampshire.

 

William Keller, Director

 

William Keller brings more than 30 years of international business and management experience in the pharmaceutical industry to his position on Alexion's Board of Directors. He is currently the General Manager of Keller Pharma Consultancy, a pharmaceutical consulting firm he founded in China. Mr. Keller is also a senior consultant to the Shanghai Foreign Investment Development Board, and serves as the Deputy General Manager of Zhangjiang Biotech & Pharmaceutical Base Development Co., Ltd.

Prior to joining Alexion, Mr. Keller held various positions with Roche Group in Asia and South America, including General Manager of Roche China Ltd. and Shanghai Roche Pharmaceutical Ltd., where he played a key role in the development of the overall Roche strategy and in the leadership of its business operations in China. Mr. Keller is the Honorary President of the R&D-based Pharmaceutical Association, the Vice Chairman of the Shanghai Association of Foreign Investment Enterprises and Chairman of the Board of Directors at Coland Pharmaceuticals. He is an Honorary Citizen of Shanghai.

Mr. Keller graduated from the School of Economics and Business Administration (Zurich).

 

John T. Mollen, Director

 

Jack Mollen has been a director of Alexion since April 2014. He was most recently special advisor to the Chairman of EMC Corporation and previously served as EMC's Executive Vice President, Human Resources (HR) for 14 years. While at EMC, Mr. Mollen led the global human resources function to ensure the availability of world-class talent to drive business success and his responsibilities included executive, leadership, and employee development; compensation and benefits; staffing; and all of the people-related aspects of acquisition integration. Prior to joining EMC, Mr. Mollen was Vice President of Human Resources at Citigroup Inc. Mr. Mollen serves as a director for a number of not-for-profit and professional boards, including the New England Healthcare Institute, the HR Policy Association, Center on Executive Compensation, Worcester Polytechnic Institute Board of Trustees and Chairman of its Compensation Committee, and as an advisory board member for Working Mother magazine.

Mr. Mollen received a bachelor's degree in economics from St. John Fisher College in Rochester, N.Y., and a master's degree in labor relations from St. Francis University in Loretto, Pa.

 

R. Douglas Norby, Director

 

R. Douglas Norby has been a director of Alexion since September 1999. Additionally, he has held positions of increasing responsibility at many companies, including serving as Sr. Vice-President and Chief Financial Officer of Tessera, Inc., a provider of intellectual property for advanced semiconductor packaging and as Senior Vice President and Chief Financial Officer of Zambeel, Inc., a data storage systems company. Mr. Norby has also held positions at Novalux, Inc., LSI Logic Corporation, Mentor Graphics Corporation and Lucasfilm, Ltd. His pharmaceutical experience includes serving as President of Pharmetrix Corporation, a drug delivery company, and as Senior Vice President and Chief Financial Officer of Syntex Corporation, a pharmaceutical company. He serves on the Board of Directors for several companies, including NEXX Systems, Inc., STATS Chip PAC, Ltd, InvenSense, Inc. and MagnaChip Semiconductor.

Mr. Norby received a B.A. in Economics from Harvard University and an M.B.A. from Harvard Business School.

 

Alvin S. Parven, Director

 

Alvin S. Parven has been a director of Alexion since May 1999. He has been President of ASP Associates, a management and strategic consulting firm, since 1997. Prior to that, Mr. Parven held positions of increasing responsibility within the Aetna family of companies, serving as Vice President at Aetna Business Consulting, Vice President, Operations at Aetna Health Plans and Vice President, Pension Services.

Mr. Parven received his B.A. from Northeastern University.

 

Andreas Rummelt, Ph.D., Director

 

Dr. Andreas Rummelt has been a director of Alexion since February 2010. He has held executive management positions internationally for more than 20 years in the pharmaceutical industry, focused in the areas of manufacturing, quality and technical matters. He is currently the CEO and Partner of InterPharmaLink AG, a management consulting firm focused on advising companies in the healthcare industry. Dr. Rummelt was Group Head of Quality Assurance and Technical Operations at Novartis, and served as a member of the Executive Committee there. He also held various positions of increasing responsibility in development for Sandoz Pharma Ltd including CEO, Head of Worldwide Technical Research and Development, Head of Technical Operations of the Novartis Pharmaceuticals Division. He currently serves on the Board of Directors at Acino, Xellia Pharmaceuticals and Selcia, Ltd.

Dr. Rummelt earned his Ph.D. in Pharmaceutical Sciences from the University of Erlangen-Nuremberg, Germany. He received executive training in general management and leadership from IMD in Lausanne (Switzerland), INSEAD in Fontainebleau (France), and Harvard Business School in Cambridge (USA).

 

Ann Veneman, Director

 

Ann M. Veneman has been a director of Alexion since May 2010. Prior to this, she has served as Executive Director of the United Nations Children's Fund (UNICEF), leading a global organization which supports multiple aspects of child health, nutrition, safety and education in over 150 countries and territories. Before joining UNICEF, Ms. Veneman was the first woman to serve as Secretary of the U.S. Department of Agriculture (USDA), leading an organization of 110,000 employees with an annual budget of $113 billion. She has also worked as California’s Secretary of Food and Agriculture. Ms. Veneman is a co-leader of the Nutrition and Physical Activity Initiative at the Bipartisan Policy Center and is a member of the Council on Foreign Relations. An attorney by training, she has practiced law in Washington, D.C. and California.

Ms. Veneman earned her Bachelor's degree in political science from the University of California, Davis; a Master's degree in public policy from the University of California, Berkeley; and a Juris Doctorate from the University of California, Hastings College of Law.